MorphoSys AG: MorphoSys Appoints Tim Demuth as New Chief Res

Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters

Related Keywords

Germany , Arizona , United States , Munich , Bayern , United Kingdom , Planegg , Massachusetts , Boston , Phoenix , Canada , Thomas Biegi , Tim Demuth , Julia Neugebauer , Eamonn Nolan , Jean Paul Kress , Marc Cluzel , Development Officer , Constellation Pharmaceutical Research , Linkedin , Xencor Inc , Twitter , Merck Co , Nasdaq , Ludwig Maximilian University , European Union , Clinical Development , Pieris Pharmaceuticals Inc , Translational Genomics Research Institute , Drug Administration , Morphosy Research , Johannes Gutenberg University , Exchange Commission , Malte Peters , Chief Research , Management Board , Chief Medical Officer , Pieris Pharmaceuticals , Supervisory Board , Constellation Pharmaceutical , Chief Executive Officer , Vice President , Global Clinical Development Oncology , Clinical Development Unit , Hematology Biopharma Development , Post Doctoral Fellow , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Morphosys , Ppoints , Demuth , Chief , Research , Development , Officer , Following , Retirement , Salte , Peters ,